Tue, March 3, 2020

Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $125 on, Mar 3rd, 2020

Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $120 to $125 on, Mar 3rd, 2020.

Matthew has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • George Farmer of "BMO Capital" Initiated at Hold and Held Target at $94 on, Tuesday, January 28th, 2020


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $164 on, Monday, March 2nd, 2020
  • Kennen MacKay of "RBC Capital" Upgraded from Hold to Buy on, Friday, January 24th, 2020
  • Gena Wang of "Barclays" Upgraded from Hold to Buy and Held Target at $98 on, Wednesday, November 27th, 2019